StockData
BioRestorative Therapies, Inc. logo

BioRestorative Therapies, Inc. (BRTX) stock

BRTXNasdaqServices-Misc Health & Allied Services, NECFiscal year ends December 31
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026Score 8/30
$1.34−0.08 (-5.63%)

Close on Nov 17, 2026Market cap $34.14MP/E –Yield –

BioRestorative Therapies r&d expenses

Research and development expenses are spending on new products and technology.

BioRestorative Therapies's R&D Expenses for the twelve months ending Mar 31, 2026 was $9.37M, up 29.2% year over year. For fiscal 2025 it was $10.09M, up 50.5% from the year before. Over ten years it grew 17.0% a year on average. The highest annual figure on record is $10.09M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$10.09M+50.5%
FY2024Dec 31, 2024$6.71M+66.2%
FY2023Dec 31, 2023$4.03M+14.8%
FY2022Dec 31, 2022$3.51M+381.9%
FY2021Dec 31, 2021$729.06K-16.9%
FY2020Dec 31, 2020$876.83K-49.1%
FY2019Dec 31, 2019$1.72M+13.8%
FY2018Dec 31, 2018$1.51M-29.7%
FY2017Dec 31, 2017$2.15M-25.4%
FY2016Dec 31, 2016$2.88M+37.0%
FY2015Dec 31, 2015$2.11M+47.1%
FY2014Dec 31, 2014$1.43M-10.3%
FY2013Dec 31, 2013$1.59M+110.6%
FY2012Dec 31, 2012$756.78K+6206.5%
FY2011Dec 31, 2011$12.00K+3.3%
FY2010Dec 31, 2010$11.62K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q1 FY2026Mar 31, 2026$1.93M-27.2%
Q4 FY2025Dec 31, 2025$2.63M+54.3%
Q3 FY2025Sep 30, 2025$2.59M+78.5%
Q2 FY2025Jun 30, 2025$2.23M+53.1%
Q1 FY2025Mar 31, 2025$2.65M+150.1%
Q4 FY2024Dec 31, 2024$1.70M+56.1%
Q3 FY2024Sep 30, 2024$1.45M+79.5%
Q2 FY2024Jun 30, 2024$1.45M+61.0%
Q1 FY2024Mar 31, 2024$1.06M-14.1%
Q4 FY2023Dec 31, 2023$1.09M+61.8%
Q3 FY2023Sep 30, 2023$809.82K-18.1%
Q2 FY2023Jun 30, 2023$902.89K-16.0%
Q1 FY2023Mar 31, 2023$1.23M+58.9%
Q4 FY2022Dec 31, 2022$673.62K+307.0%
Q3 FY2022Sep 30, 2022$989.17K+316.7%
Q2 FY2022Jun 30, 2022$1.08M+568.3%
Q1 FY2022Mar 31, 2022$775.34K+369.2%
Q4 FY2021Dec 31, 2021$165.50K-7.0%
Q3 FY2021Sep 30, 2021$237.41K-5.4%
Q2 FY2021Jun 30, 2021$160.90K-38.5%
Q1 FY2021Mar 31, 2021$165.25K-11.3%
Q4 FY2020Dec 31, 2020$177.91K-57.2%
Q3 FY2020Sep 30, 2020$251.04K-38.7%
Q2 FY2020Jun 30, 2020$261.55K-40.8%
Q1 FY2020Mar 31, 2020$186.33K-59.0%
Q4 FY2019Dec 31, 2019$415.79K+10.7%
Q3 FY2019Sep 30, 2019$409.82K+14.7%
Q2 FY2019Jun 30, 2019$441.72K+18.5%
Q1 FY2019Mar 31, 2019$455.01K+11.8%
Q4 FY2018Dec 31, 2018$375.77K+53.2%
Q3 FY2018Sep 30, 2018$357.44K-27.2%
Q2 FY2018Jun 30, 2018$372.82K-39.0%
Q1 FY2018Mar 31, 2018$407.13K-49.5%
Q4 FY2017Dec 31, 2017$245.20K-67.4%
Q3 FY2017Sep 30, 2017$490.65K-25.2%
Q2 FY2017Jun 30, 2017$610.73K+0.3%
Q1 FY2017Mar 31, 2017$805.85K–
Q4 FY2016Dec 31, 2016$752.66K–
Q3 FY2016Sep 30, 2016$656.17K–
Q2 FY2016Jun 30, 2016$608.69K–

More BioRestorative Therapies figures

See a number that looks wrong?